Summit Therapeutics Inc. Revenue From Contracts With Customers
Summit Therapeutics Inc. (SMMT) reported Revenue From Contracts With Customers of GBP 253.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueFromContractsWithCustomers · last filed 2020-06-02
- Summit Therapeutics Inc. revenue from contracts with customers for the quarter ending 2020-03-31 was 253.00K GBP, a 1.61% increase year-over-year.
- Summit Therapeutics Inc. revenue from contracts with customers for the quarter ending 2019-10-31 was 124.00K GBP, a 81.63% decline year-over-year.
- Summit Therapeutics Inc. revenue from contracts with customers for the quarter ending 2019-07-31 was 126.00K GBP, a 99.67% decline year-over-year.
- Summit Therapeutics Inc. revenue from contracts with customers for the quarter ending 2019-04-30 was 249.00K GBP, a 93.57% decline year-over-year.
| Period end | Revenue From Contracts With Customers 3 month | Revenue From Contracts With Customers 6 month | Revenue From Contracts With Customers 9 month | Revenue From Contracts With Customers 11 month | Revenue From Contracts With Customers 12 month |
|---|---|---|---|---|---|
| 2020-03-31 | 253.00K GBP 6-K · filed 2020-06-02 | ||||
| 2019-12-31 | 583.00K GBP 20-F · filed 2020-04-30 | ||||
| 2019-10-31 | 124.00K GBP 6-K · filed 2019-12-17 | 250.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | 499.00K GBP 6-K · filed 2019-12-17 | ||
| 2019-07-31 | 126.00K GBP 6-K · filed 2019-10-11 | 375.00K GBP 6-K · filed 2019-10-11 | |||
| 2019-04-30 | 249.00K GBP 6-K · filed 2019-06-12 | ||||
| 2019-03-31 | 375.00K GBP 6-K · filed 2020-06-02 | ||||
| 2019-01-31 | 505.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 1.18M GBP derived: sum of 2 quarters · filed 2020-04-30 | 39.14M GBP derived: sum of 3 quarters · filed 2020-04-30 | 43.01M GBP 20-F · filed 2020-04-30 | |
| 2018-10-31 | 675.00K GBP 6-K · filed 2019-12-17 | 38.63M GBP derived: sum of 2 quarters · filed 2019-12-17 | 42.51M GBP 6-K · filed 2019-12-17 | 45.76M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-07-31 | 37.96M GBP 6-K · filed 2019-10-11 | 41.83M GBP 6-K · filed 2019-10-11 | 45.08M GBP derived: sum of 3 quarters · filed 2020-04-30 | 47.71M GBP derived: sum of 4 quarters · filed 2020-04-30 | |
| 2018-04-30 | 3.87M GBP 6-K · filed 2019-06-12 | 7.12M GBP derived: sum of 2 quarters · filed 2020-04-30 | 9.76M GBP derived: sum of 3 quarters · filed 2020-04-30 | ||
| 2018-01-31 | 3.25M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | 5.88M GBP derived: sum of 2 quarters · filed 2020-04-30 | 12.36M GBP 20-F · filed 2020-04-30 | ||
| 2017-10-31 | 2.63M GBP 6-K · filed 2018-12-11 | 9.11M GBP 6-K · filed 2018-12-11 | |||
| 2017-01-31 | 2.30M GBP 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |